FDA approves Bristol Myers Squibb’s Opdivo for expanded lung cancer treatment, boosting stock and investor sentiment
In a significant step forward for lung cancer treatment, the US Food and Drug Administration (FDA) has expanded its approval of Bristol Myers Squibb's Opdivo ... Read More
Johnson & Johnson’s RYBREVANT approved by FDA as second-line option for EGFR-mutated NSCL
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's RYBREVANT (amivantamab-vmjw) in combination with chemotherapy for the treatment of adult patients with ... Read More
EC approves AstraZeneca’s Tagrisso with chemotherapy for EGFR-mutated lung cancer
AstraZeneca has received approval from the European Commission (EC) to use its cancer drug, Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy as a ... Read More
Roche reports setback in lung cancer study with tiragolumab and tecentriq combination
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced disappointing results from the phase II/III SKYSCRAPER-06 study, aimed at evaluating the efficacy of tiragolumab plus Tecentriq ... Read More
GSK announces significant survival results for Jemperli in endometrial cancer trial
In a significant development for patients with primary advanced or recurrent endometrial cancer, GSK plc (LSE/NYSE: GSK) has disclosed promising outcomes for Jemperli (dostarlimab-gxly) from ... Read More
Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More
Venus Remedies expands cancer drug portfolio in South Eastern Europe
In a significant development for its oncology portfolio in South Eastern Europe, Venus Remedies Ltd has been granted marketing authorization from Serbia for chemotherapy drugs ... Read More
AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in ... Read More
Gilead gets Trodelvy FDA approval for pre-treated HR+/HER2- metastatic breast cancer
Gilead Sciences has secured the approval of the US Food and Drug Administration (FDA) for Trodelvy (sacituzumab govitecan-hziy) for pre-treated HR+/HER2- metastatic breast cancer. The ... Read More
Gilead gets Trodelvy FDA priority review for pre-treated HR+/HER2- metastatic breast cancer
Gilead Sciences said that Trodelvy (sacituzumab govitecan-hziy) has been granted priority review from the US Food and Drug Administration (FDA) for the treatment of another ... Read More